Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

• Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).• High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19.• IL-6...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of infectious diseases Vol. 95; pp. 332 - 339
Main Authors Zhu, Zhe, Cai, Ting, Fan, Lingyan, Lou, Kehong, Hua, Xin, Huang, Zuoan, Gao, Guosheng
Format Journal Article
LanguageEnglish
Published Canada Elsevier Ltd 01.06.2020
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
Elsevier
Subjects
Online AccessGet full text
ISSN1201-9712
1878-3511
1878-3511
DOI10.1016/j.ijid.2020.04.041

Cover

Loading…
Abstract • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).• High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19.• IL-6 has the highest predictive value among other single immune-inflammatory parameters. The risk model based on IL-6, CRP and hypertension enlarged the predictability.• The dynamic change of IL-6 in the severe cases were parallel to the amelioration of this disease, implied a potential value for monitoring the process of severe cases. To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
AbstractList • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).• High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19.• IL-6 has the highest predictive value among other single immune-inflammatory parameters. The risk model based on IL-6, CRP and hypertension enlarged the predictability.• The dynamic change of IL-6 in the severe cases were parallel to the amelioration of this disease, implied a potential value for monitoring the process of severe cases. To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).OBJECTIVETo explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.METHODS127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.RESULTSOf 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.CONCLUSIONOur study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
• Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19). • High level of interleukin-6 (IL-6), C-reactive protein (CRP) and hypertension were independent predictors for the severity of COVID-19. • IL-6 has the highest predictive value among other single immune-inflammatory parameters. The risk model based on IL-6, CRP and hypertension enlarged the predictability. • The dynamic change of IL-6 in the severe cases were parallel to the amelioration of this disease, implied a potential value for monitoring the process of severe cases.
Objective: To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods: 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Results: Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Conclusion: Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
Author Cai, Ting
Zhu, Zhe
Gao, Guosheng
Huang, Zuoan
Lou, Kehong
Hua, Xin
Fan, Lingyan
Author_xml – sequence: 1
  givenname: Zhe
  surname: Zhu
  fullname: Zhu, Zhe
  email: zhuzhemcgrady@163.com
  organization: Department of Blood Transfusion, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, PR China
– sequence: 2
  givenname: Ting
  surname: Cai
  fullname: Cai, Ting
  email: caiting@nbu.edu.cn
  organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China
– sequence: 3
  givenname: Lingyan
  surname: Fan
  fullname: Fan, Lingyan
  email: lingyan@163.com
  organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China
– sequence: 4
  givenname: Kehong
  surname: Lou
  fullname: Lou, Kehong
  email: 516616952@qq.com
  organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China
– sequence: 5
  givenname: Xin
  surname: Hua
  fullname: Hua, Xin
  email: 619223610@qq.com
  organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China
– sequence: 6
  givenname: Zuoan
  surname: Huang
  fullname: Huang, Zuoan
  email: huangzuoannb@163.com
  organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China
– sequence: 7
  givenname: Guosheng
  surname: Gao
  fullname: Gao, Guosheng
  email: 495926922@qq.com
  organization: Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32334118$$D View this record in MEDLINE/PubMed
BookMark eNqFUktr3DAQNiWlebR_oIfiYy_e6mVbKqUQljYJBHppz2IsjRNtbWsryQv77yt3t6HJIYUBDdL3GDTfeXEy-QmL4i0lK0po82GzchtnV4wwsiIiF31RnFHZyorXlJ7knhFaqZay0-I8xg0hRDSNfFWccsa5oFSeFWY9uMkZGModDDOWvi_dOM4TVm7qBxhHSD7syy0EGDFhiGXyJcSIMXf3WEbcYXBpvxCND36CnQtzLK2LCBHLPIF6XbzsYYj45nheFD--fvm-vq5uv13drC9vK9NwmSrbdLYxvWJM9pT2YPqethxtU6uGceyEqhm2TCgOXQuEMEsUxZ6g4lQaSfhFcXPQtR42ehvcCGGvPTj958KHOw0hOTOgNgKMaIDUqq2F7Vols1HHQWVHYe2i9fmgtZ27Ea3BKQUYHok-fpncvb7zO91SVRPCs8D7o0Dwv2aMSY8uGhwGmNDPUTOuhJS8FQv03b9eDyZ_t5QB7AAwwccYsH-AUKKXKOiNXqKglyhoInLRTJJPSMYlSM4v87rheeqnAxXztnYOg47G4WTQuoAm5e90z9M_PqGbY8h-4v5_5N9Vc-Ok
CitedBy_id crossref_primary_10_1186_s13018_020_01702_w
crossref_primary_10_1002_rmv_2146
crossref_primary_10_1111_ijlh_13412
crossref_primary_10_1186_s40560_021_00531_1
crossref_primary_10_3389_fncel_2021_748136
crossref_primary_10_1590_1414_431x2021e11711
crossref_primary_10_1007_s11897_021_00505_2
crossref_primary_10_1136_bmj_m1328
crossref_primary_10_2147_IDR_S321915
crossref_primary_10_1016_j_ijid_2021_01_059
crossref_primary_10_1093_ajcp_aqaa205
crossref_primary_10_4103_jdmimsu_jdmimsu_230_22
crossref_primary_10_2139_ssrn_3949424
crossref_primary_10_12688_f1000research_132157_1
crossref_primary_10_36106_ijar_3001402
crossref_primary_10_3389_fimmu_2022_978619
crossref_primary_10_3390_vaccines10111818
crossref_primary_10_24293_ijcpml_v29i2_1997
crossref_primary_10_1371_journal_pone_0279935
crossref_primary_10_1016_j_ajem_2021_01_006
crossref_primary_10_1177_1751143720969587
crossref_primary_10_1186_s42269_022_00856_3
crossref_primary_10_3389_fcell_2022_914781
crossref_primary_10_29296_25877305_2024_06_16
crossref_primary_10_1016_j_imu_2021_100564
crossref_primary_10_4103_NJM_NJM_142_20
crossref_primary_10_1186_s12876_022_02132_0
crossref_primary_10_5005_jp_journals_10006_2010
crossref_primary_10_1016_j_intimp_2023_110626
crossref_primary_10_36425_rehab104997
crossref_primary_10_1007_s12250_021_00425_4
crossref_primary_10_1002_rmv_70026
crossref_primary_10_1016_j_medine_2020_12_001
crossref_primary_10_46235_1028_7221_13945_IAB
crossref_primary_10_29328_journal_jprr_1001019
crossref_primary_10_1038_s41392_021_00849_0
crossref_primary_10_4103_abr_abr_257_23
crossref_primary_10_3389_fmed_2021_588013
crossref_primary_10_1002_jmv_26346
crossref_primary_10_3389_fpsyt_2023_1241190
crossref_primary_10_1111_1744_9987_14108
crossref_primary_10_4103_bbrj_bbrj_188_20
crossref_primary_10_1371_journal_pone_0241541
crossref_primary_10_1136_bmjopen_2020_044640
crossref_primary_10_1016_j_carbpol_2022_120350
crossref_primary_10_1177_08850666211045626
crossref_primary_10_3390_life11030182
crossref_primary_10_3748_wjg_v27_i24_3516
crossref_primary_10_3390_jcm11041011
crossref_primary_10_3390_covid3060059
crossref_primary_10_1089_jir_2022_0029
crossref_primary_10_2174_1874285802115010077
crossref_primary_10_1002_jja2_12838
crossref_primary_10_1016_j_eclinm_2020_100527
crossref_primary_10_1055_s_0043_1772595
crossref_primary_10_3389_fmed_2022_988666
crossref_primary_10_4103_cmrp_cmrp_113_22
crossref_primary_10_1007_s10875_020_00821_7
crossref_primary_10_2147_IJGM_S355083
crossref_primary_10_1017_S0950268821000078
crossref_primary_10_1002_med_21997
crossref_primary_10_3390_brainsci12020250
crossref_primary_10_1080_14740338_2021_1946513
crossref_primary_10_3389_fmed_2020_00301
crossref_primary_10_1002_ejsc_12262
crossref_primary_10_1186_s12879_021_06623_5
crossref_primary_10_1016_j_ajem_2020_10_022
crossref_primary_10_1038_s41598_024_70172_5
crossref_primary_10_1016_j_cca_2023_117586
crossref_primary_10_1016_j_jelectrocard_2021_01_012
crossref_primary_10_3390_jcm10184142
crossref_primary_10_3390_life13010186
crossref_primary_10_3389_fphar_2022_973587
crossref_primary_10_7861_clinmed_21_2_s36
crossref_primary_10_3390_diagnostics11081327
crossref_primary_10_1016_j_abst_2022_10_001
crossref_primary_10_1097_MD_0000000000031138
crossref_primary_10_4103_ajim_ajim_77_21
crossref_primary_10_1128_mBio_01372_21
crossref_primary_10_3390_medicina58020144
crossref_primary_10_1016_j_medin_2020_07_007
crossref_primary_10_1007_s12291_020_00897_3
crossref_primary_10_3389_fmed_2020_00431
crossref_primary_10_1016_j_eclinm_2020_100550
crossref_primary_10_1016_j_cegh_2021_100727
crossref_primary_10_1016_j_heliyon_2021_e06155
crossref_primary_10_12688_f1000research_125115_1
crossref_primary_10_12688_f1000research_125115_2
crossref_primary_10_1371_journal_pone_0253894
crossref_primary_10_3389_fimmu_2022_986950
crossref_primary_10_1002_clc_23465
crossref_primary_10_1016_j_heliyon_2024_e27251
crossref_primary_10_1016_j_intimp_2022_109428
crossref_primary_10_1507_endocrj_EJ20_0443
crossref_primary_10_1007_s13318_020_00668_8
crossref_primary_10_1016_j_cyto_2023_156287
crossref_primary_10_3389_fimmu_2020_01518
crossref_primary_10_3389_fimmu_2021_593595
crossref_primary_10_1016_j_autneu_2021_102903
crossref_primary_10_4103_ecdt_ecdt_2_22
crossref_primary_10_18772_26180197_2020_v2n2a3
crossref_primary_10_2196_23390
crossref_primary_10_1136_postgradmedj_2021_139939
crossref_primary_10_1002_jcb_30683
crossref_primary_10_3389_fphar_2022_973246
crossref_primary_10_7554_eLife_79946
crossref_primary_10_1002_iid3_471
crossref_primary_10_1016_j_jaci_2020_05_008
crossref_primary_10_1016_j_mayocpiqo_2021_01_009
crossref_primary_10_3390_ijerph20032146
crossref_primary_10_1016_j_freeradbiomed_2025_01_015
crossref_primary_10_3390_jcm10091924
crossref_primary_10_1016_j_jaip_2020_06_039
crossref_primary_10_1002_bies_202000094
crossref_primary_10_1371_journal_pbio_3001109
crossref_primary_10_7759_cureus_57336
crossref_primary_10_1093_trstmh_trad012
crossref_primary_10_1111_iji_12605
crossref_primary_10_1002_rmv_2195
crossref_primary_10_1016_j_bios_2024_116618
crossref_primary_10_1016_j_ijid_2020_10_003
crossref_primary_10_4103_jcsr_jcsr_66_22
crossref_primary_10_1016_j_arcmed_2021_06_004
crossref_primary_10_1002_jcla_24881
crossref_primary_10_3389_fphar_2022_802228
crossref_primary_10_1177_00045632211011194
crossref_primary_10_1177_10760296211010973
crossref_primary_10_1155_2023_7258585
crossref_primary_10_1515_tjb_2020_0624
crossref_primary_10_12688_f1000research_146814_1
crossref_primary_10_1155_2022_7920915
crossref_primary_10_3389_fphar_2022_853496
crossref_primary_10_3389_fimmu_2023_1197467
crossref_primary_10_1080_19390211_2022_2075072
crossref_primary_10_3389_fimmu_2020_603389
crossref_primary_10_1016_j_prp_2021_153610
crossref_primary_10_1002_jmv_27800
crossref_primary_10_1186_s12964_021_00754_7
crossref_primary_10_1038_s41598_023_37846_y
crossref_primary_10_1002_jmv_26836
crossref_primary_10_1080_08039488_2022_2116106
crossref_primary_10_14412_1995_4484_2020_245_261
crossref_primary_10_4103_ijpm_ijpm_658_21
crossref_primary_10_1016_j_biopha_2020_110698
crossref_primary_10_1016_j_jaip_2020_10_043
crossref_primary_10_1002_jmv_26166
crossref_primary_10_1080_08820139_2020_1773850
crossref_primary_10_1007_s00421_021_04668_7
crossref_primary_10_3233_THC_220321
crossref_primary_10_3390_v15091925
crossref_primary_10_3390_life14020163
crossref_primary_10_1038_s41421_021_00305_x
crossref_primary_10_1016_j_clim_2020_108615
crossref_primary_10_1017_S1047951124000283
crossref_primary_10_31363_2313_7053_2024_794
crossref_primary_10_4103_jpbs_JPBS_655_20
crossref_primary_10_1007_s10157_021_02101_z
crossref_primary_10_1016_j_amjoto_2020_102796
crossref_primary_10_1371_journal_ppat_1009865
crossref_primary_10_1186_s12911_020_01338_0
crossref_primary_10_3389_fmed_2021_699607
crossref_primary_10_1177_1753466620933508
crossref_primary_10_1007_s11739_021_02750_8
crossref_primary_10_26442_00403660_2022_01_201323
crossref_primary_10_3390_v14061188
crossref_primary_10_1186_s41983_023_00784_7
crossref_primary_10_1016_j_cyto_2021_155428
crossref_primary_10_3889_oamjms_2022_8545
crossref_primary_10_1210_clinem_dgad284
crossref_primary_10_1080_17843286_2020_1822078
crossref_primary_10_1038_s41538_024_00261_2
crossref_primary_10_3389_fmed_2023_1252556
crossref_primary_10_36106_ijsr_7525405
crossref_primary_10_1016_j_mehy_2020_110208
crossref_primary_10_1093_ajcn_nqab426
crossref_primary_10_36660_ijcs_20200150
crossref_primary_10_1016_j_bvth_2024_100034
crossref_primary_10_1016_j_smim_2021_101508
crossref_primary_10_1016_j_freeradbiomed_2021_01_044
crossref_primary_10_3390_jcm10020297
crossref_primary_10_3390_vaccines10081233
crossref_primary_10_18410_jebmh_2021_466
crossref_primary_10_36106_ijsr_8404512
crossref_primary_10_1080_02770903_2021_1888116
crossref_primary_10_3390_vaccines10101764
crossref_primary_10_1093_ndt_gfad111
crossref_primary_10_1007_s11596_021_2320_7
crossref_primary_10_1186_s12879_021_05847_9
crossref_primary_10_1007_s10787_022_01047_2
crossref_primary_10_1186_s13293_021_00363_6
crossref_primary_10_1007_s10238_021_00708_w
crossref_primary_10_1007_s12519_020_00368_y
crossref_primary_10_2478_abm_2022_0020
crossref_primary_10_1016_j_ajem_2020_05_022
crossref_primary_10_1177_0885066620969132
crossref_primary_10_1038_s41598_024_71569_y
crossref_primary_10_1038_s41598_021_92885_7
crossref_primary_10_1016_j_ajem_2020_09_018
crossref_primary_10_3390_biomedinformatics3020023
crossref_primary_10_3390_diagnostics12081847
crossref_primary_10_1002_ams2_683
crossref_primary_10_1007_s12192_023_01330_3
crossref_primary_10_17116_oftalma2021137052331
crossref_primary_10_1002_jcla_23911
crossref_primary_10_1016_j_intimp_2021_108255
crossref_primary_10_3390_pathogens11020195
crossref_primary_10_1002_rmv_2221
crossref_primary_10_1007_s00421_022_05126_8
crossref_primary_10_3390_ijerph19031172
crossref_primary_10_1002_edm2_338
crossref_primary_10_1002_hsr2_868
crossref_primary_10_1371_journal_pone_0302977
crossref_primary_10_33713_egetbd_1167278
crossref_primary_10_3390_pathogens10091105
crossref_primary_10_1177_20503121221108613
crossref_primary_10_1177_11772719221106600
crossref_primary_10_1007_s12016_021_08908_8
crossref_primary_10_1002_jmv_27297
crossref_primary_10_2139_ssrn_3951144
crossref_primary_10_3389_fcell_2021_578825
crossref_primary_10_2174_1381612827666210311141512
crossref_primary_10_7759_cureus_15235
crossref_primary_10_1016_j_cyto_2021_155455
crossref_primary_10_3390_biomedicines12092055
crossref_primary_10_1515_biol_2022_0502
crossref_primary_10_3389_fneur_2020_01031
crossref_primary_10_3390_jcm11102945
crossref_primary_10_35366_104875
crossref_primary_10_1016_j_ejphar_2023_176061
crossref_primary_10_2298_MPNS2312344B
crossref_primary_10_1017_S0950268821002545
crossref_primary_10_1155_2022_4461647
crossref_primary_10_12688_f1000research_74023_1
crossref_primary_10_2174_1871529X21666211201110007
crossref_primary_10_36740_WLek202104144
crossref_primary_10_12688_f1000research_74023_2
crossref_primary_10_1038_s41598_024_81225_0
crossref_primary_10_1155_2022_2755246
crossref_primary_10_1016_j_intimp_2021_107828
crossref_primary_10_1002_jmv_26411
crossref_primary_10_1186_s12879_023_08816_6
crossref_primary_10_4103_cjhr_cjhr_87_24
crossref_primary_10_4103_jmms_jmms_3_21
crossref_primary_10_1155_2022_4161235
crossref_primary_10_3389_fbioe_2020_00916
crossref_primary_10_1016_j_cyto_2023_156445
crossref_primary_10_1016_j_bbadis_2024_167472
crossref_primary_10_18087_cardio_2020_6_n1226
crossref_primary_10_1056_NEJMra2026131
crossref_primary_10_4103_ejh_ejh_3_22
crossref_primary_10_3389_fimmu_2021_666223
crossref_primary_10_4103_jpbs_jpbs_88_23
crossref_primary_10_1007_s11655_021_3350_5
crossref_primary_10_1371_journal_pone_0271807
crossref_primary_10_3233_CH_200978
crossref_primary_10_1186_s12879_021_06457_1
crossref_primary_10_1002_agm2_12149
crossref_primary_10_1371_journal_pone_0283469
crossref_primary_10_4103_jfmpc_jfmpc_2196_20
crossref_primary_10_1038_s41392_021_00764_4
crossref_primary_10_3390_ijerph18105342
crossref_primary_10_3390_jcm11082235
crossref_primary_10_1177_1060028021999473
crossref_primary_10_1186_s12879_020_05619_x
crossref_primary_10_4103_jodp_jodp_46_23
crossref_primary_10_1016_j_cytogfr_2022_07_002
crossref_primary_10_53730_ijhs_v5nS1_15129
crossref_primary_10_1002_jmv_29935
crossref_primary_10_1136_bcr_2020_236720
crossref_primary_10_3389_fneur_2021_657004
crossref_primary_10_3389_fmed_2021_780750
crossref_primary_10_3389_fpls_2022_780257
crossref_primary_10_1177_87551225221104323
crossref_primary_10_17749_2313_7347_ob_gyn_rep_2021_249
crossref_primary_10_3389_fimmu_2021_742941
crossref_primary_10_1186_s12985_024_02400_3
crossref_primary_10_1016_j_jpsychires_2021_07_027
crossref_primary_10_4102_ajlm_v9i1_1282
Cites_doi 10.1038/s41579-018-0118-9
10.1007/s00259-020-04735-9
10.1101/2020.03.01.20029769
10.1016/S0140-6736(20)30154-9
10.1038/nri3552
10.1038/nm1267
10.1016/j.ijid.2020.03.004
10.1089/jir.2019.0085
10.1101/2020.02.07.937862
10.1101/2020.02.12.945576
10.3390/jcm9010267
10.1038/cmi.2015.74
10.1002/jmv.25748
10.1084/jem.20171773
10.21203/rs.3.rs-19346/v1
10.2217/imt-2016-0020
10.1007/s00281-017-0639-8
10.1101/2020.02.10.20021584
10.1007/s00281-017-0629-x
10.1074/jbc.M210429200
10.1101/2020.02.16.20023671
10.1093/cid/ciaa272
10.3201/eid1005.030640
10.1001/jama.2020.1585
10.1101/2020.01.22.914952
ContentType Journal Article
Copyright 2020 The Author(s)
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
2020 The Author(s) 2020
Copyright_xml – notice: 2020 The Author(s)
– notice: Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
– notice: 2020 The Author(s) 2020
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1016/j.ijid.2020.04.041
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic



MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1878-3511
EndPage 339
ExternalDocumentID oai_doaj_org_article_c4ac46a059754db7983edb3a91734dd0
PMC7195003
32334118
10_1016_j_ijid_2020_04_041
S1201971220302575
Genre Journal Article
GroupedDBID ---
--K
.1-
.FO
.~1
0R~
1B1
1P~
1~.
1~5
29J
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
7X7
88E
8C1
8FI
8FJ
8FQ
8R4
8R5
AAEDW
AAFWJ
AAIKJ
AALRI
AAQFI
AAQXK
AARKO
AAXUO
AAYWO
ABBQC
ABFRF
ABMAC
ABUWG
ABWVN
ACGFO
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AFTJW
AGEKW
AGHFR
AGQPQ
AGYEJ
AHMBA
AIGII
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BR6
BVXVI
CCPQU
CS3
DIK
DU5
DWQXO
E3Z
EBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FNPLU
FYUFA
G-Q
GBLVA
GROUPED_DOAJ
GX1
HMCUK
HVGLF
HZ~
IHE
IXB
J1W
KQ8
M1P
M3C
M3G
M41
MO0
N9A
O-L
O9-
OD-
OK1
OO.
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
Q2X
Q38
QTD
R2-
ROL
RPZ
RWL
RXW
SDF
SDG
SEL
SES
SEW
SSZ
TAE
UKHRP
UNMZH
Z5R
0SF
3V.
6I.
AACTN
AAFTH
ABVKL
AFCTW
NCXOZ
RIG
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c638t-d6bd6cf9228f11facff173ed659623eb4952e72493ab7a002d091ef0e9318c803
IEDL.DBID IXB
ISSN 1201-9712
1878-3511
IngestDate Wed Aug 27 01:30:17 EDT 2025
Thu Aug 21 14:03:36 EDT 2025
Thu Jul 10 22:32:10 EDT 2025
Wed Feb 19 02:11:53 EST 2025
Tue Jul 01 04:29:52 EDT 2025
Thu Apr 24 22:51:12 EDT 2025
Fri Feb 23 02:48:03 EST 2024
Tue Aug 26 16:33:04 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
SARS-CoV-2
Cytokine storm
IL-6
Immune-inflammatory parameters
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c638t-d6bd6cf9228f11facff173ed659623eb4952e72493ab7a002d091ef0e9318c803
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributed equally.
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S1201971220302575
PMID 32334118
PQID 2394883743
PQPubID 23479
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_c4ac46a059754db7983edb3a91734dd0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7195003
proquest_miscellaneous_2394883743
pubmed_primary_32334118
crossref_primary_10_1016_j_ijid_2020_04_041
crossref_citationtrail_10_1016_j_ijid_2020_04_041
elsevier_sciencedirect_doi_10_1016_j_ijid_2020_04_041
elsevier_clinicalkey_doi_10_1016_j_ijid_2020_04_041
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-06-01
PublicationDateYYYYMMDD 2020-06-01
PublicationDate_xml – month: 06
  year: 2020
  text: 2020-06-01
  day: 01
PublicationDecade 2020
PublicationPlace Canada
PublicationPlace_xml – name: Canada
PublicationTitle International journal of infectious diseases
PublicationTitleAlternate Int J Infect Dis
PublicationYear 2020
Publisher Elsevier Ltd
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
– name: Elsevier
References Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al., Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Stu***dy Gro***up. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.07.937862.
Chousterman, Swirski, Weber (bib0030) 2017; 39
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. doi:https://doi.org/10.1101/2020.01.22.914952.
Peng Y, Meng K, Guan H, Leng L, Zhu R, Wang B, et al., Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chinese Journal of Cardiology 2020. doi: 10.3760/cma.j.cn112148-20200220-00105.
Chen, Zhou, Dong, Qu, Gong, Han (bib0020) 2020; 395
Chen, Thai, Zhao, Ho, DeSouza, Wu (bib0025) 2003; 278
Wang, Sheng, Fang, Chen, Wang, Yu (bib0120) 2004; 10
Liu, Zhou, Yang (bib0075) 2016; 13
Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020. doi: 10.1016/j.ijid.2020.03.004.
Hotchkiss, Monneret, Payen (bib0055) 2013; 13
Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, et al., Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.12.945576.
Chen C, Chen C, Yan J, Zhou N, Zhao J, Wang D. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese Journal of Cardiology. doi: 10.3760/cma.j.cn112148-20200225-00123.
Chan, Yuan, Kok, To, Chu, Yang (bib0005) 2020; 395
Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020. doi: 10.1002/jmv.25748.
Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al., The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020. doi: https://doi.org/10.1101/2020.03.01.20029769.
Channappanavar, Perlman (bib0010) 2017; 39
Guo, Cao, Hong, Tan, Chen, Jin (bib0045) 2020; 7
Xu, Yu, Qu, Zhang, Jiang, Huang (bib0140) 2020; 47
Kuba, Imai, Rao, Gao, Guo, Guan (bib0060) 2005; 11
Povlsen, Grimm, Wehland, Infanger, Kruger (bib0095) 2020; 9
Tanaka, Narazaki, Kishimoto (bib0105) 2016; 8
Gupta, Khan, Singh (bib0050) 2020; 40
Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al., Neutrophil-to-Lymphocyte Ratio Predicts Severe illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.10.20021584.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585.
Shi Y, Ou J, Chen X, Tan M, Li F, Liu Y. Expressions of multiple inflammation markers in the patients with 2019 novel coronavirus pneumonia and their clinical values. Chinese Journal of Laboratory Medicine 2020. doi: 10.3760/cma.j.cn114452-20200214-00073.
Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al., Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.16.20023671.
Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa272.
Wang C, Xie J, Zhao L, Fe X, Zhang H, Tan Y, et al., Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19. 25 March 2020, PREPRINT (Version 1) available at Research Square [+https://doi.org/10.21203/rs.3.rs-19346/v1+].
Cui, Li, Shi (bib0035) 2019; 17
Norlander, Madhur, Harrison (bib0085) 2018; 215
10.1016/j.ijid.2020.04.041_bib0100
10.1016/j.ijid.2020.04.041_bib0145
10.1016/j.ijid.2020.04.041_bib0125
Chousterman (10.1016/j.ijid.2020.04.041_bib0030) 2017; 39
Chen (10.1016/j.ijid.2020.04.041_bib0020) 2020; 395
Chan (10.1016/j.ijid.2020.04.041_bib0005) 2020; 395
Kuba (10.1016/j.ijid.2020.04.041_bib0060) 2005; 11
Norlander (10.1016/j.ijid.2020.04.041_bib0085) 2018; 215
Guo (10.1016/j.ijid.2020.04.041_bib0045) 2020; 7
10.1016/j.ijid.2020.04.041_bib0090
10.1016/j.ijid.2020.04.041_bib0070
10.1016/j.ijid.2020.04.041_bib0150
10.1016/j.ijid.2020.04.041_bib0130
10.1016/j.ijid.2020.04.041_bib0110
10.1016/j.ijid.2020.04.041_bib0135
10.1016/j.ijid.2020.04.041_bib0015
Povlsen (10.1016/j.ijid.2020.04.041_bib0095) 2020; 9
10.1016/j.ijid.2020.04.041_bib0115
Wang (10.1016/j.ijid.2020.04.041_bib0120) 2004; 10
Hotchkiss (10.1016/j.ijid.2020.04.041_bib0055) 2013; 13
Gupta (10.1016/j.ijid.2020.04.041_bib0050) 2020; 40
Chen (10.1016/j.ijid.2020.04.041_bib0025) 2003; 278
Xu (10.1016/j.ijid.2020.04.041_bib0140) 2020; 47
Tanaka (10.1016/j.ijid.2020.04.041_bib0105) 2016; 8
Cui (10.1016/j.ijid.2020.04.041_bib0035) 2019; 17
Channappanavar (10.1016/j.ijid.2020.04.041_bib0010) 2017; 39
Liu (10.1016/j.ijid.2020.04.041_bib0075) 2016; 13
10.1016/j.ijid.2020.04.041_bib0080
10.1016/j.ijid.2020.04.041_bib0040
10.1016/j.ijid.2020.04.041_bib0065
References_xml – reference: Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, et al., Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.12.945576.
– reference: Peng Y, Meng K, Guan H, Leng L, Zhu R, Wang B, et al., Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chinese Journal of Cardiology 2020. doi: 10.3760/cma.j.cn112148-20200220-00105.
– reference: Shi Y, Ou J, Chen X, Tan M, Li F, Liu Y. Expressions of multiple inflammation markers in the patients with 2019 novel coronavirus pneumonia and their clinical values. Chinese Journal of Laboratory Medicine 2020. doi: 10.3760/cma.j.cn114452-20200214-00073.
– volume: 11
  start-page: 875
  year: 2005
  end-page: 879
  ident: bib0060
  article-title: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
  publication-title: Nat Med
– volume: 40
  start-page: 19
  year: 2020
  end-page: 23
  ident: bib0050
  article-title: Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health
  publication-title: J Interferon Cytokine Res
– reference: Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020. doi: 10.1002/jmv.25748.
– reference: Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa272.
– reference: Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020. doi: 10.1016/j.ijid.2020.03.004.
– volume: 47
  start-page: 1275
  year: 2020
  end-page: 1280
  ident: bib0140
  article-title: Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2
  publication-title: Eur J Nucl Med Mol Imaging
– reference: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585.
– volume: 10
  start-page: 818
  year: 2004
  end-page: 824
  ident: bib0120
  article-title: Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients
  publication-title: Emerg Infect Dis
– reference: Wang C, Xie J, Zhao L, Fe X, Zhang H, Tan Y, et al., Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19. 25 March 2020, PREPRINT (Version 1) available at Research Square [+https://doi.org/10.21203/rs.3.rs-19346/v1+].
– reference: Chen C, Chen C, Yan J, Zhou N, Zhao J, Wang D. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese Journal of Cardiology. doi: 10.3760/cma.j.cn112148-20200225-00123.
– volume: 395
  start-page: 514
  year: 2020
  end-page: 523
  ident: bib0005
  article-title: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
  publication-title: Lancet
– volume: 13
  start-page: 3
  year: 2016
  end-page: 10
  ident: bib0075
  article-title: The cytokine storm of severe influenza and development of immunomodulatory therapy
  publication-title: Cell Mol Immunol
– volume: 8
  start-page: 959
  year: 2016
  end-page: 970
  ident: bib0105
  article-title: Immunotherapeutic implications of IL-6 blockade for cytokine storm
  publication-title: Immunotherapy
– volume: 13
  start-page: 862
  year: 2013
  end-page: 874
  ident: bib0055
  article-title: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
  publication-title: Nat Rev Immunol
– volume: 395
  start-page: 507
  year: 2020
  end-page: 513
  ident: bib0020
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan
  publication-title: China: a descriptive study. Lancet
– reference: Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al., Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.16.20023671.
– volume: 7
  start-page: 11
  year: 2020
  ident: bib0045
  article-title: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
  publication-title: Mil Med Res
– volume: 9
  start-page: 267
  year: 2020
  ident: bib0095
  article-title: The Vasoactive Mas Receptor in Essential Hypertension
  publication-title: J Clin Med
– reference: Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al., Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Stu***dy Gro***up. bioRxiv 2020. doi: https://doi.org/10.1101/2020.02.07.937862.
– volume: 39
  start-page: 529
  year: 2017
  end-page: 539
  ident: bib0010
  article-title: Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
  publication-title: Semin Immunopathol
– volume: 278
  start-page: 17036
  year: 2003
  end-page: 17043
  ident: bib0025
  article-title: Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop
  publication-title: J Biol Chem
– volume: 215
  start-page: 21
  year: 2018
  end-page: 33
  ident: bib0085
  article-title: The immunology of hypertension
  publication-title: J Exp Med
– reference: Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. doi:https://doi.org/10.1101/2020.01.22.914952.
– reference: Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al., Neutrophil-to-Lymphocyte Ratio Predicts Severe illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.10.20021584.
– reference: Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al., The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020. doi: https://doi.org/10.1101/2020.03.01.20029769.
– volume: 17
  start-page: 181
  year: 2019
  end-page: 192
  ident: bib0035
  article-title: Origin and evolution of pathogenic coronaviruses
  publication-title: Nat Rev Microbiol
– volume: 39
  start-page: 517
  year: 2017
  end-page: 528
  ident: bib0030
  article-title: Cytokine storm and sepsis disease pathogenesis
  publication-title: Semin Immunopathol
– volume: 17
  start-page: 181
  issue: 3
  year: 2019
  ident: 10.1016/j.ijid.2020.04.041_bib0035
  article-title: Origin and evolution of pathogenic coronaviruses
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-018-0118-9
– ident: 10.1016/j.ijid.2020.04.041_bib0015
– volume: 7
  start-page: 11
  issue: 1
  year: 2020
  ident: 10.1016/j.ijid.2020.04.041_bib0045
  article-title: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
  publication-title: Mil Med Res
– volume: 47
  start-page: 1275
  issue: 5
  year: 2020
  ident: 10.1016/j.ijid.2020.04.041_bib0140
  article-title: Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-020-04735-9
– ident: 10.1016/j.ijid.2020.04.041_bib0080
  doi: 10.1101/2020.03.01.20029769
– ident: 10.1016/j.ijid.2020.04.041_bib0090
– volume: 395
  start-page: 514
  issue: 10223
  year: 2020
  ident: 10.1016/j.ijid.2020.04.041_bib0005
  article-title: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30154-9
– volume: 13
  start-page: 862
  issue: 12
  year: 2013
  ident: 10.1016/j.ijid.2020.04.041_bib0055
  article-title: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3552
– volume: 11
  start-page: 875
  issue: 8
  year: 2005
  ident: 10.1016/j.ijid.2020.04.041_bib0060
  article-title: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
  publication-title: Nat Med
  doi: 10.1038/nm1267
– ident: 10.1016/j.ijid.2020.04.041_bib0135
  doi: 10.1016/j.ijid.2020.03.004
– volume: 395
  start-page: 507
  issue: 10223
  year: 2020
  ident: 10.1016/j.ijid.2020.04.041_bib0020
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan
  publication-title: China: a descriptive study. Lancet
– volume: 40
  start-page: 19
  issue: 1
  year: 2020
  ident: 10.1016/j.ijid.2020.04.041_bib0050
  article-title: Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/jir.2019.0085
– ident: 10.1016/j.ijid.2020.04.041_bib0040
  doi: 10.1101/2020.02.07.937862
– ident: 10.1016/j.ijid.2020.04.041_bib0150
  doi: 10.1101/2020.02.12.945576
– volume: 9
  start-page: 267
  issue: 1
  year: 2020
  ident: 10.1016/j.ijid.2020.04.041_bib0095
  article-title: The Vasoactive Mas Receptor in Essential Hypertension
  publication-title: J Clin Med
  doi: 10.3390/jcm9010267
– volume: 13
  start-page: 3
  issue: 1
  year: 2016
  ident: 10.1016/j.ijid.2020.04.041_bib0075
  article-title: The cytokine storm of severe influenza and development of immunomodulatory therapy
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2015.74
– ident: 10.1016/j.ijid.2020.04.041_bib0125
  doi: 10.1002/jmv.25748
– volume: 215
  start-page: 21
  issue: 1
  year: 2018
  ident: 10.1016/j.ijid.2020.04.041_bib0085
  article-title: The immunology of hypertension
  publication-title: J Exp Med
  doi: 10.1084/jem.20171773
– ident: 10.1016/j.ijid.2020.04.041_bib0110
  doi: 10.21203/rs.3.rs-19346/v1
– volume: 8
  start-page: 959
  issue: 8
  year: 2016
  ident: 10.1016/j.ijid.2020.04.041_bib0105
  article-title: Immunotherapeutic implications of IL-6 blockade for cytokine storm
  publication-title: Immunotherapy
  doi: 10.2217/imt-2016-0020
– volume: 39
  start-page: 517
  issue: 5
  year: 2017
  ident: 10.1016/j.ijid.2020.04.041_bib0030
  article-title: Cytokine storm and sepsis disease pathogenesis
  publication-title: Semin Immunopathol
  doi: 10.1007/s00281-017-0639-8
– ident: 10.1016/j.ijid.2020.04.041_bib0070
  doi: 10.1101/2020.02.10.20021584
– volume: 39
  start-page: 529
  issue: 5
  year: 2017
  ident: 10.1016/j.ijid.2020.04.041_bib0010
  article-title: Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
  publication-title: Semin Immunopathol
  doi: 10.1007/s00281-017-0629-x
– volume: 278
  start-page: 17036
  issue: 19
  year: 2003
  ident: 10.1016/j.ijid.2020.04.041_bib0025
  article-title: Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M210429200
– ident: 10.1016/j.ijid.2020.04.041_bib0065
  doi: 10.1101/2020.02.16.20023671
– ident: 10.1016/j.ijid.2020.04.041_bib0130
  doi: 10.1093/cid/ciaa272
– volume: 10
  start-page: 818
  issue: 5
  year: 2004
  ident: 10.1016/j.ijid.2020.04.041_bib0120
  article-title: Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1005.030640
– ident: 10.1016/j.ijid.2020.04.041_bib0115
  doi: 10.1001/jama.2020.1585
– ident: 10.1016/j.ijid.2020.04.041_bib0100
– ident: 10.1016/j.ijid.2020.04.041_bib0145
  doi: 10.1101/2020.01.22.914952
SSID ssj0004668
Score 2.648697
Snippet • Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19).•...
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). 127 consecutive hospitalized...
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).OBJECTIVETo explore the clinical...
• Clinical characteristics and immune-inflammatory parameters were compared between non-severe and severe patients with coronavirus disease 2019 (COVID-19). •...
Objective: To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods: 127 consecutive...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 332
SubjectTerms Adult
Aged
Betacoronavirus
C-Reactive Protein - analysis
Coronavirus Infections - etiology
Coronavirus Infections - immunology
COVID-19
Cytokine storm
Female
Humans
Hypertension - complications
IL-6
Immune-inflammatory parameters
Interleukin-6 - blood
Male
Middle Aged
Pandemics
Pneumonia, Viral - etiology
Pneumonia, Viral - immunology
Risk Factors
SARS-CoV-2
Severity of Illness Index
SummonAdditionalLinks – databaseName: DOAJ: Directory of Open Access Journal (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na90wDBejhzEYY-u-si882G2EJbYTJ8dtrJRBd1qhN-NPltLmlb739vdPip3QbNBeBjkldhLLsiVZ0k8AH5zhUdGhu488lrKXTWla7kourDTeurb2dA558qM9PpXfz5qzG6W-KCYswQMnwn1y0jjZGtQCVCO9VX0ngrfCoJkhpPeTtY4ybzamlozIlASH4q3sVc1zukyK7BrOB8II5dUEcirrlUiakPtXkulfzfPvAMobEunoMTzKqiT7nIbwBO6F8RDun2Rn-SE8TEdyLGUaPQWXMUAvGCF8B7aJbKDskFAilyFjXE4Od0Zg4JcUJLNluw0zk1OYoZrI8E8Dlbqjjo6AD8zv4Xq_ZdnHw5AK_TM4Pfr28-txmWsslA5X3q70rfWtiz3nXazraFyMSNjgW6rKI4JF-4kHhTaaMFYZ3D49EjvEKvS4GbiuEs_hYNyM4SWwrml803T4UBlpK2FiUMYL4QmSXnFTQD2TWbsMQE51MC70HGl2rmlqNE2NriRedQEflz5XCX7j1tZfaPaWlgSdPd1AhtKZofRdDFWAmOdez9mpuJ_ii4ZbP90svbLuknSSO_u9n9lL48Imb40Zw2a_1VSzvusEangFvEjstgxMcIHaR90VoFaMuBr5-sk4_JrAwxXV_a3Eq_9BqtfwgIaSIufewMHueh_eoo62s--m5fgHyxI46Q
  priority: 102
  providerName: Directory of Open Access Journals
Title Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1201971220302575
https://dx.doi.org/10.1016/j.ijid.2020.04.041
https://www.ncbi.nlm.nih.gov/pubmed/32334118
https://www.proquest.com/docview/2394883743
https://pubmed.ncbi.nlm.nih.gov/PMC7195003
https://doaj.org/article/c4ac46a059754db7983edb3a91734dd0
Volume 95
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9UwEA7rPoggoutlj5dDBN-knubSpn10F5dFWUF04byFNBftstsu5-Kjv92ZND1sFVYQSqFp0uYymUwyM98Q8sYaHhQeurvAQyZrWWSm5DbjopHGNbZkDs8hzz6Xp-fy47JY7pHj0RcGzSoT7x94euTWKWWRenNx3baLrwzWrloxzoFOgfDQ0VzIKjrxLY9u-EYO7nCQOcPcyXFmsPFqL1pEC-V5hDuVbLI4RQz_yRr1twz6pynljbXp5CF5kIRK-n6o9yOy57sDcvcsqc0PyP3hcI4OPkePiU1ooJcUsb497QNt0U_EZ0BvQCJXUfVOERb8Cs1l1nTTUxPVwxQERgo19Rj0DgtahEAwP9vVdk2Ttodilz0h5ycfvh2fZinaQmZhDm4yVzautKHmvAqMBWNDYEp4V2J8HuEb2Elxr2C3JkyjDDBSB6KGD7mvgS3YKhdPyX7Xd_6Q0KooXFFU8FIZ2eTCBK-ME8IhOL3iZkbY2M3aJihyjIhxqUebswuNQ6NxaHQu4WIz8nZX5noA4rg19xGO3i4ngmjHhH71XScq0lYaK0sDAqYqpGtUXUFzG2FgByukc_mMiHHs9einCpwVPtTe-utiV2pCyf8s93okLw1THPU2pvP9dq0xen1VCZD1ZuTZQG67hgkuQA5h1YyoCSFOWj5907U_Ioy4wgjAuXj-n_V9Qe7h02A295Lsb1Zb_woEtE0zJ3fe_WLzeLwxj7MR7p--VL8BvW47_w
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELZKkQAJIShXOI3EG4o2PhJnH2lFtYVuX2ilfbMcH5CqTao9-vs7kzirBqQiIeUpthMfn8dje-YbQj5bw4PCQ3cXeEjlVOapKbhNuaikcZUtmMNzyPlJMTuT3xf5YoccDL4waFYZZX8v0ztpHd9MYm9Orup68pPB2jVVjHPAKQAvv0fugzZQILSPFvu3nCN7fzjInWL26DnTG3nV5zXShfKs4zuVbLQ6dST-o0XqbyX0T1vKW4vT4VPyJGqV9Gtf8Wdkxzd75ME83pvvkcf96RztnY6eExvpQC8okn172gZao6OITwFwgJHL7u6dIi_4JdrLrOi6paa7H6agMVKoqceod1jQIgeCua6XmxWN1z0U--wFOTv8dnowS2O4hdTCJFynrqhcYcOU8zIwFowNgSnhXYEBeoSvYCvFvYLtmjCVMiBJHegaPmR-CnLBlpl4SXabtvGvCS3z3OV5CYnKyCoTJnhlnBAO2ekVNwlhQzdrG7nIMSTGhR6Mzs41Do3GodGZhIcl5Mu2zFXPxHFn7n0cvW1OZNHuXrTLXzrCSFtprCwMaJgql65S0xKaWwkDW1ghncsSIoax14OjKohW-FB956_zbakRlP9Z7tMALw1zHC9uTOPbzUpj-PqyFKDsJeRVD7dtwwQXoIiwMiFqBMRRy8cpTf274xFXGAI4E2_-s74fycPZ6fxYHx-d_HhLHmFKb0P3juyulxv_HrS1dfWhm403beo8Pg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+value+of+immune-inflammatory+parameters+to+assess+the+severity+of+coronavirus+disease+2019&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Zhu%2C+Zhe&rft.au=Cai%2C+Ting&rft.au=Fan%2C+Lingyan&rft.au=Lou%2C+Kehong&rft.date=2020-06-01&rft.eissn=1878-3511&rft.volume=95&rft.spage=332&rft_id=info:doi/10.1016%2Fj.ijid.2020.04.041&rft_id=info%3Apmid%2F32334118&rft.externalDocID=32334118
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon